EPH Receptor A4 Antikörper (C-Term)

Produktnummer ABIN7877361

Der Kaninchen Polyklonal anti-EPH Receptor A4 Antikörper wird verwendet zum Nachweis von EPH Receptor A4 in Proben von Human. Er wurde validiert für WB.

Kurzübersicht für EPH Receptor A4 Antikörper (C-Term) (ABIN7877361)

Target: EPH Receptor A4 (EPHA4)

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser EPH Receptor A4 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Produktdetails anti-EPH Receptor A4 Antikörper

Bindungsspezifität: C-Term

Verwendungszweck: EPHA4 Antibody / Ephrin type-A receptor 4

Aufreinigung: Immunogen affinity purified

Immunogen: A synthetic peptide corresponding to a sequence at the C-terminus of human EPHA4 was used as the immunogen for the EPHA4 antibody.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the EPHA4 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: After reconstitution, the EPHA4 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Details zu EPH Receptor A4

Target: EPH Receptor A4 (EPHA4)

Andere Bezeichnung: EPHA4

Hintergrund: EPHA4 antibody detects Ephrin type-A receptor 4, a receptor tyrosine kinase that mediates axon guidance, cell adhesion, and tissue patterning through bidirectional ephrin signaling. EPHA4 belongs to the Eph receptor family, the largest group of receptor tyrosine kinases in vertebrates. The EPHA4 antibody is used extensively in neuroscience, developmental biology, and cancer research to investigate cell-cell communication and guidance signaling.

EPHA4 is encoded by the EPHA4 gene on human chromosome 2q36.1. The receptor consists of an extracellular ligand-binding domain, a cysteine-rich region, two fibronectin type III repeats, a single transmembrane domain, and an intracellular kinase domain. EPHA4 binds both ephrin-A and ephrin-B ligands, enabling cross-class signaling that regulates axonal navigation, synaptic plasticity, and tissue boundary formation.

The EPHA4 antibody detects a 120-130 kilodalton transmembrane receptor by western blot. Activation of EPHA4 by ephrin ligands triggers receptor autophosphorylation, recruitment of adaptor proteins, and cytoskeletal reorganization via Rho GTPase signaling. This leads to growth cone collapse and repulsion, essential for proper neural circuit formation.

In the central nervous system, EPHA4 influences axon pathfinding in the corticospinal tract and regulates synapse formation and plasticity. It is also implicated in spinal cord injury response, where its inhibition promotes axonal regeneration. Outside the nervous system, EPHA4 modulates angiogenesis, epithelial morphogenesis, and tumor progression. Overexpression has been observed in breast, prostate, and colorectal cancers, correlating with invasive behavior and poor prognosis.

EPHA4 signaling crosstalks with pathways including MAPK, PI3K-Akt, and JAK-STAT, integrating environmental cues with cell motility and survival. Genetic ablation in animal models results in abnormal axon targeting and motor coordination defects. NSJ Bioreagents provides a validated EPHA4 antibody optimized for western blot, supporting comprehensive investigation of receptor tyrosine kinase signaling, neural development, and cancer cell dynamics.

UniProt: P54764

Pathways: RTK Signalweg